---
layout: post
title: Seattle Biotech 2010
date: '2006-02-17T07:56:00.000-08:00'
author: Richard Sprague
tags: 
modified_time: '2007-03-10T02:33:46.523-08:00'
blogger_id: tag:blogger.com,1999:blog-8203221.post-114036459435446959
blogger_orig_url: http://blog.richardsprague.com/2006/02/seattle-biotech-2010.html
---

<strong><span style="font-family:Book Antiqua;">Seattle Biotech 2010</span></strong><br /><span style="font-family:Book Antiqua;">The IndUS Entrepreneurs sponsored </span><a href="http://www.tieapp.com/Products/EventsCalendar/portal_skins/custom/EventDetailView?id:int=975&org_id=tieseattle&amp;user_role=None&admin_role=None">Seattle Biotech 2010: Opportunities and Challenges</a><span style="font-family:Book Antiqua;"> on Thursday night at the Bellevue Courtyard Marriott.</span><br /><span style="font-family:Book Antiqua;"></span><br /><span style="font-family:Book Antiqua;">Panelists:</span><br /><ul><li><span style="font-family:Book Antiqua;">Susannah Malarkey (moderator), Exec Director, Technology Alliance</span></li><br /><li><span style="font-family:Book Antiqua;">Sanjaya Joshi, Userspace: made an opening presentation</span></li><br /><li><span style="font-family:Book Antiqua;">Greg Bear, science fiction author</span></li><br /><li><span style="font-family:Book Antiqua;">Robert DuBose, Director of Bioinformatics, Amgen</span></li><br /><li><span style="font-family:Book Antiqua;">Christopher Elias, CEO, PATH</span></li><br /><li><span style="font-family:Book Antiqua;">Bruce Montgomery, Corus Pharma</span></li><br /><li><span style="font-family:Book Antiqua;">David Shubert, Accelerator Corp</span></li><br /><li><span style="font-family:Book Antiqua;">Chad Waite, OVP</span></li><br /><li><span style="font-family:Book Antiqua;">Paul Yager, Univ of Wash</span></li></ul><span style="font-family:Book Antiqua;"></span><br /><span style="font-family:Book Antiqua;">The Seattle biotech community is surprisingly strong, with a rich history traced from the 1973 opening of the Fred Hutchinson Cancer Research Center, and a trove of alumni companies. Many companies owe their roots to Robert Nowinski and several other serial entrepreneurs, all the way to the Allen Brain Atlas, funded by Paul Allen.  Seattle has also been a powerhouse for medical equipment makers, including ultrasound.</span><br /><span style="font-family:Book Antiqua;"></span><br /><span style="font-family:Book Antiqua;">Bioterror is getting all the attention and huge amounts of money, so that was a subject of many discussions. I was surprised to hear the panelists speculate about the 2001 anthrax killer. One guy thinks it’s a 12-25 year-old self-taught loner. I had thought </span><a href="http://www.anthraxinvestigation.com/AnthraxFoster.pdf">Steve Hatfill was still the prime suspect</a><span style="font-family:Book Antiqua;">, even if he hasn’t been accused.</span><br /><span style="font-family:Book Antiqua;"></span><br /><ul><li><span style="font-family:Book Antiqua;">“Aspirin would never pass a Phase II trial”.</span></li><br /><li><span style="font-family:Book Antiqua;">“The Gates Foundation spends 2x WHO” on medical treatment for the developing countries.</span></li><br /><li><span style="font-family:Book Antiqua;">Nanotech is the first innovation since globalization, says John Martin of the Washington Tech Alliance, so it’s less likely that a “hub” will form in a single region. You’ll see nanotech happening worldwide, in surprising places.</span></li><br /><li><span style="font-family:Book Antiqua;">Research on treatments that only benefit the third world may not seem profitable, but focus on process improvements required to get to low prices is very effective.</span></li></ul><span style="font-family:Book Antiqua;"></span>